Testing Antifungal Therapy for Crohn's Disease
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding an antifungal drug (fluconazole) to standard Crohn's disease treatment helps improve symptoms. It's for people with mild to moderate Crohn's who have not used antifungal medications recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have mild to moderate Crohn's disease
- You have not taken antifungal medication in the past month
- You are not allergic to fluconazole
- You do not have serious liver, kidney, or heart problems
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This trial tests whether a fecal transplant (putting healthy bacteria into your gut) combined with dietary changes can help control active Crohn's disease. It is for people who need stronger treatments or have stopped responding to their current therapy.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.